Skip to main content
Clinical Trials/NCT05732311
NCT05732311
Recruiting
Not Applicable

Intermittent Theta Burst Stimulation for Maintenance Therapy in Depression

Berthold Langguth, MD, Ph.D.1 site in 1 country60 target enrollmentApril 25, 2023
ConditionsDepression

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Depression
Sponsor
Berthold Langguth, MD, Ph.D.
Enrollment
60
Locations
1
Primary Endpoint
relapse (number of patients who have a relapse for depression)
Status
Recruiting
Last Updated
5 months ago

Overview

Brief Summary

This is a randomized, multi-center, open-label study in which patients with depression who responded to an open-label treatment with intermittent theta burst stimulation (iTBS) will receive this procedure as maintenance therapy. The patients will be randomized to two study arms. The arms differ in the frequency of stimulation (standard iTBS (5 treatments every working day for one week) vs. accelerated iTBS (5 treatments in one day)). For purposes of effect size estimation an interim analysis will be done after half of the patients.

Registry
clinicaltrials.gov
Start Date
April 25, 2023
End Date
February 28, 2026
Last Updated
5 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Berthold Langguth, MD, Ph.D.
Responsible Party
Sponsor Investigator
Principal Investigator

Berthold Langguth, MD, Ph.D.

Prof. Dr.

University of Regensburg

Eligibility Criteria

Inclusion Criteria

  • adult women and men aged 18 to 70 years with an ICD-10 diagnosis of a depressive episode of depressive disorder (F32), recurrent depressive disorder (F33), or bipolar disorder (F31)
  • moderate or severe current episode prior to initial open iTBS treatment (HAMD-21 \>16 points)
  • response to iTBS treatment (either reduction in HAMD score by 50% or score at the end of treatment \<11 points)
  • no concomitant psychotic symptoms.
  • no other relevant psychiatric disorder as assessed by the study physician
  • residence in Germany and German speaking that allows understanding of the information provided
  • patient is capable of giving consent

Exclusion Criteria

  • fulfillment of the general contraindications for TMS (electrical implants or metallic objects in the body such as pacemakers or insulin pumps).
  • severe neurological diseases (e.g., cerebrovascular events, neurodegenerative diseases, epilepsy, malformations of the brain, severe head injury in the history)
  • current harmful use or dependence on alcohol, amphetamines, cocaine, benzodiazepines, anticonvulsants, or opiates
  • acute suicidality
  • pregnancy
  • current participation in another study

Outcomes

Primary Outcomes

relapse (number of patients who have a relapse for depression)

Time Frame: 33 weeks

50% increase of symptoms according to Hamilton depression rating scale

Secondary Outcomes

  • Major Depression Inventory(49 weeks)
  • Columbia-Suicide Severity Rating Scale(49 weeks)
  • Beck Anxiety Index(49 weeks)
  • Hamilton Depression Rating Scale(49 weeks)
  • World Health Organisation quality of life bref(49 weeks)
  • clinical global impression(49 weeks)
  • Global Assessment of Functioning(49 weeks)

Study Sites (1)

Loading locations...

Similar Trials